|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.51 USD | +5.42% |
|
+7.88% | +38.11% |
| 22/07 | Celldex Therapeutics, Inc. - Special Call | |
| 22/07 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
| Market Cap | 279.27Cr 245.4Cr 229.06Cr 210.22Cr 393.51Cr 27TCr 403.22Cr 2.72TCr 1.06TCr 13TCr 1.05TCr 1.03TCr 46TCr | P/E 2026 * |
-8.2x | P/E 2027 * | -8.2x |
|---|---|---|---|---|---|
| Enterprise Value | 220.86Cr 194.07Cr 181.15Cr 166.25Cr 311.21Cr 21TCr 318.88Cr 2.15TCr 840.08Cr 10TCr 829.23Cr 811.23Cr 36TCr | EV / Sales 2026 * |
914x | EV / Sales 2027 * | 206x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +5.42% | ||
| 1 week | +7.88% | ||
| Current month | +0.81% | ||
| 1 month | +0.19% | ||
| 3 months | +16.71% | ||
| 6 months | +51.92% | ||
| Current year | +38.11% |
| 1 week | 33.97 |  | 37.76 |
| 1 month | 33.37 | | 40.3 |
| Current year | 22.33 | | 40.3 |
| 1 year | 19.72 | | 40.3 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/06/26 | Free | Chief Financial Officer | 93,000 | 0.1185% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.42% | +7.88% | +70.89% | +6.08% | 279.27Cr | |
| +2.61% | +1.91% | +1.70% | +13.91% | 4.79TCr | |
| -1.60% | -1.15% | +388.84% | +589.22% | 3.91TCr | |
| -0.98% | +2.28% | +7.02% | +52.74% | 3.67TCr | |
| +1.90% | +24.70% | +27.25% | +10.64% | 4.05TCr | |
| +1.47% | +4.90% | +6.48% | +43.52% | 2.8TCr | |
| -0.94% | +0.05% | - | - | 1.68TCr | |
| +2.44% | +10.76% | +30.59% | +131.04% | 1.59TCr | |
| +0.18% | -1.46% | +4.92% | +10.14% | 1.36TCr | |
| -1.14% | +6.52% | -3.80% | -29.13% | 1.38TCr | |
| Average | +0.88% | +4.17% | +59.32% | +92.02% | 2.55TCr | |
| Weighted average by Cap. | +0.57% | +5.00% | +73.54% | +122.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.16L 21.23L 19.82L 18.19L 34.05L 23Cr 34.89L 2.35Cr 91.91L 11Cr 90.72L 88.76L 40Cr | 1.1Cr 97.03L 90.57L 83.12L 1.56Cr 105.77Cr 1.59Cr 11Cr 4.2Cr 52Cr 4.15Cr 4.06Cr 180.93Cr |
| Net income | -33Cr -29Cr -27Cr -25Cr -47Cr -3.16TCr -48Cr -321.02Cr -125.54Cr -1.56TCr -123.92Cr -121.23Cr -5.41TCr | -37Cr -32Cr -30Cr -28Cr -52Cr -3.52TCr -53Cr -357.42Cr -139.78Cr -1.74TCr -137.97Cr -134.98Cr -6.02TCr |
| Net Debt | -58Cr -51Cr -48Cr -44Cr -82Cr -5.59TCr -84Cr -568.11Cr -222.17Cr -2.77TCr -219.31Cr -214.54Cr -9.57TCr | -52Cr -45Cr -42Cr -39Cr -73Cr -4.93TCr -74Cr -500.97Cr -195.91Cr -2.44TCr -193.39Cr -189.19Cr -8.44TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | $37.51 | +5.42% | 15,72,485 |
| 28/26/28 | $35.58 | -0.20% | 5,65,896 |
| 27/26/27 | $35.65 | +1.05% | 10,40,865 |
| 24/26/24 | $35.28 | -0.40% | 6,39,231 |
| 23/26/23 | $35.42 | +1.87% | 8,56,468 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
